Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with …

M Stevenson, R Archer, J Tosh… - Health Technology …, 2016 - eprints.whiterose.ac.uk
OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with
increasing disability, reduced quality of life and substantial costs (as a result of both …

Osteoimmunology: major and costimulatory pathway expression associated with chronic inflammatory induced bone loss

TN Crotti, AA Dharmapatni, E Alias… - Journal of immunology …, 2015 - Wiley Online Library
The field of osteoimmunology has emerged in response to the range of evidences
demonstrating the close interrelationship between the immune system and bone …

[HTML][HTML] Rheumatoid Arthritis: Early diagnosis and treatment outcomes

B Heidari - Caspian journal of internal medicine, 2011 - ncbi.nlm.nih.gov
Rheumatoid arthritis (RA) is an inflammatory progressive disease which in the absence of
appropriate treatment can lead to joint destruction and disability. Prognosis of RA may be …

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for …

J Detert, H Bastian, J Listing, A Weiß… - Annals of the …, 2013 - ard.bmj.com
Objective To investigate the long-term effects of induction therapy with adalimumab (ADA)
plus methotrexate (MTX) in comparison with placebo (PBO) plus MTX in DMARD-naïve …

Cost-effectiveness of biosimilars vs leflunomide in patients with rheumatoid arthritis

K Peng, SCW Chan, Y Wang, FWT Cheng… - JAMA Network …, 2024 - jamanetwork.com
Importance Among patients with rheumatoid arthritis (RA) who had an inadequate response
to methotrexate, a treatment sequence initiated with biosimilar disease-modifying …

[HTML][HTML] Challenges in the development and reimbursement of personalized medicine—payer and manufacturer perspectives and implications for health economics …

E Faulkner, L Annemans, L Garrison, M Helfand… - Value in Health, 2012 - Elsevier
Background Personalized medicine technologies can improve individual health by
delivering the right dose of the right drug to the right patient at the right time but create …

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of …

M Schoels, J Wong, DL Scott, A Zink… - Annals of the …, 2010 - ard.bmj.com
Objective To review the cost effectiveness of rheumatoid arthritis (RA) treatments and inform
the clinical recommendations by the European League Against Rheumatism. Methods A …

The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review

JT Joensuu, S Huoponen, KJ Aaltonen, YT Konttinen… - PloS one, 2015 - journals.plos.org
Background and Objectives Economic evaluations provide information to aid the optimal
utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) …

How to get the most from methotrexate (MTX) treatment for your rheumatoid arthritis patient?—MTX in the treat-to-target strategy

PC Taylor, A Balsa Criado, AB Mongey… - Journal of clinical …, 2019 - mdpi.com
Methotrexate (MTX) is a remarkable drug with a key role in the management of rheumatoid
arthritis (RA) at every stage of its evolution. Its attributes include good overall efficacy for …

Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change

I Ordas, BG Feagan, WJ Sandborn - Gut, 2011 - gut.bmj.com
Crohn's disease is a chronic inflammatory disorder that follows a progressive and
destructive course. Ultimately, uncontrolled inflammation leads to bowel damage from …